| Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing A Amabile, A Migliara, P Capasso, M Biffi, D Cittaro, L Naldini, ... Cell 167 (1), 219-232. e14, 2016 | 512 | 2016 |
| Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology OM Pello, M De Pizzol, M Mirolo, L Soucek, L Zammataro, A Amabile, ... Blood, The Journal of the American Society of Hematology 119 (2), 411-421, 2012 | 395 | 2012 |
| TRPML1 links lysosomal calcium to autophagosome biogenesis through the activation of the CaMKKβ/VPS34 pathway A Scotto Rosato, S Montefusco, C Soldati, S Di Paola, A Capuozzo, ... Nature communications 10 (1), 5630, 2019 | 168 | 2019 |
| Bisphosphonates target B cells to enhance humoral immune responses E Tonti, NJ de Oya, G Galliverti, EA Moseman, P Di Lucia, A Amabile, ... Cell reports 5 (2), 323-330, 2013 | 48 | 2013 |
| Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling C Adamopoulos, TA Ahmed, MR Tucker, PMU Ung, M Xiao, Z Karoulia, ... Cancer discovery 11 (7), 1716-1735, 2021 | 46 | 2021 |
| Sampling the host response to SARS-CoV-2 in hospitals under siege AW Charney, NW Simons, K Mouskas, L Lepow, E Cheng, J Le Berichel, ... Nature Medicine 26 (8), 1157-1158, 2020 | 31 | 2020 |
| Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I−/− iPSCs for β cell replacement R Chimienti, T Baccega, S Torchio, F Manenti, S Pellegrini, A Cospito, ... Cell reports 40 (13), 2022 | 15 | 2022 |
| IL10RB as a key regulator of COVID-19 host susceptibility and severity G Voloudakis, G Hoffman, S Venkatesh, KM Lee, K Dobrindt, JM Vicari, ... medRxiv, 2021 | 15 | 2021 |
| Permanent Epigenetic Gene Silencing L Naldini, AL Lombardo, A Amabile, A Migliara US Patent App. 15/521,294, 2019 | 13 | 2019 |
| AXL limits the mobilization of cholesterol to regulate dendritic cell maturation and the immunogenic response to cancer M Belabed, MD Park, CM Blouin, S Balan, CY Moon, J Boumelha, ... bioRxiv, 2023.12. 25.573303, 2023 | 4 | 2023 |
| Ovarian cancer-derived IL-4 promotes immunotherapy resistance G Mollaoglu, A Tepper, C Falcomatà, HT Potak, L Pia, A Amabile, ... Cell 187 (26), 7492-7510. e22, 2024 | 3 | 2024 |
| Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSER1 gene BM Santoliquido, M Frenquelli, C Contadini, S Bestetti, M Gaviraghi, ... Life Science Alliance 4 (8), 2021 | 3 | 2021 |
| 729. Inheritable Silencing of Endogenous Gene by Hit-and-Run Targeted Epigenetic Editing A Amabile, A Migliara, P Capasso, M Biffi, L Naldini, A Lombardo Molecular Therapy 24, S287-S288, 2016 | 1 | 2016 |
| Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer M Belabed, MD Park, CM Blouin, S Balan, CY Moon, G Freed, ... Nature Immunology, 1-12, 2025 | | 2025 |
| Bispecific antibody targeting of lipid nanoparticles A Amabile, M Phelan, Z Yu, P Silva, A Marks, J Morla-Folch, M Sohn, ... bioRxiv, 2024.12. 20.629467, 2024 | | 2024 |
| Abstract B014: Spatial genomics identifies cancer cell cytokines regulating ovarian cancer immunity G Mollaoglu, A Tepper, H Potak, L Pia, A Amabile, C Falcomata, ... Cancer Immunology Research 11 (12_Supplement), B014-B014, 2023 | | 2023 |
| Permanent Epigenetic Gene Silencing L Naldini, AL Lombardo, A Amabile, A Migliara US Patent App. 17/963,631, 2023 | | 2023 |
| Gene silencing L Naldini, AL Lombardo, A AMABILE, A MIGLIARA | | 2022 |
| Pysyvä epigeneettinen geenien vaimennus L Naldini, AL Lombardo, A Amabile, A Migliara | | 2022 |
| Permanent epigenetisk gen-inaktivering (gene silencing) L Naldini, AL Lombardo, A Amabile, A Migliara | | 2022 |
